Skip to content

AnaptysBio

US · ANAB #3010 by market cap Listed 2017
46.63 -0.77 -1.62%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:30

Recent news

  • Rating change
    TD Cowen Maintains AnaptysBio(ANAB.US) With Buy Rating
    Market Newswire · 2026/8/25
  • Rating change
    TD Cowen Maintains AnaptysBio(ANAB.US) With Buy Rating, Cuts Target Price to $70
    Market Newswire · 2026/8/25
  • Rating change
    A Quick Look at Today's Ratings for AnaptysBio(ANAB.US), With a Forecast Between $75 to $93
    Market Newswire · 2026/5/13
  • Rating change
    TD Cowen Maintains AnaptysBio(ANAB.US) With Buy Rating, Maintains Target Price $75
    Market Newswire · 2026/7/13
  • Rating change
    UBS Maintains AnaptysBio(ANAB.US) With Buy Rating, Raises Target Price to $76
    Market Newswire · 2026/5/13
  • Rating change
    Piper Sandler Maintains AnaptysBio(ANAB.US) With Buy Rating, Cuts Target Price to $93
    Market Newswire · 2026/5/4
  • Rating change
    Leerink Partners Maintains AnaptysBio(ANAB.US) With Buy Rating, Raises Target Price to $90
    Market Newswire · 2026/5/15
  • Rating change
    J.P. Morgan Maintains AnaptysBio(ANAB.US) With Buy Rating, Raises Target Price to $70
    Market Newswire · 2026/5/23
  • Rating change
    H.C. Wainwright Initiates AnaptysBio(ANAB.US) With Buy Rating, Announces Target Price $95
    Market Newswire · 2026/6/10
  • Rating change
    Leerink Partners Maintains AnaptysBio(ANAB.US) With Buy Rating
    Market Newswire · 2026/5/27
  • Rating change
    Leerink Partners Maintains AnaptysBio(ANAB.US) With Buy Rating, Announces Target Price $85
    Market Newswire · 2026/4/28
  • H.C. Wainwright Maintains AnaptysBio(ANAB.US) With Buy Rating, Maintains Target Price $95
    Market Newswire · 2026/11/13
  • Leerink Partners Maintains AnaptysBio(ANAB.US) With Buy Rating, Maintains Target Price $81
    Market Newswire · 2026/10/22
  • Company notice
    AnaptysBio: Anaptys Biosciences, Inc. - Distribution Option Symbol: ANAB New Symbol: ANAB1
    OCC · 2026/4/7
  • Piper Sandler Maintains AnaptysBio(ANAB.US) With Buy Rating, Maintains Target Price $93
    Market Newswire · 2026/11/13
  • Rating change
    UBS Maintains AnaptysBio(ANAB.US) With Buy Rating, Maintains Target Price $76
    Market Newswire · 2026/9/22
  • Rating change
    Leerink Partners Maintains AnaptysBio(ANAB.US) With Buy Rating, Announces Target Price $81
    Market Newswire · 2026/9/23
  • Barclays Maintains AnaptysBio(ANAB.US) With Buy Rating, Maintains Target Price $75
    Market Newswire · 2026/11/14
  • Earnings Flash (ANAB) AnaptysBio, Inc. Reports Q1 Revenue $30.3M, Vs. FactSet Est of $18.9M
    MT Newswires · 2026/11/13
  • Rating change
    J.P. Morgan Maintains AnaptysBio(ANAB.US) With Buy Rating, Cuts Target Price to $60
    Market Newswire · 2026/9/30
  • Rating change
    TD Cowen Maintains AnaptysBio(ANAB.US) With Buy Rating, Announces Target Price $75
    Market Newswire · 2026/4/27
  • Rating change
    Piper Sandler Maintains AnaptysBio(ANAB.US) With Buy Rating, Maintains Target Price $93
    Market Newswire · 2026/7/22
  • H.C. Wainwright Maintains AnaptysBio(ANAB.US) With Buy Rating, Maintains Target Price $95
    Market Newswire · 2026/10/26
  • Rating change
    Barclays Maintains AnaptysBio(ANAB.US) With Buy Rating, Maintains Target Price $75
    Market Newswire · 2026/9/23
  • H.C. Wainwright Maintains AnaptysBio(ANAB.US) With Buy Rating, Maintains Target Price $95
    Market Newswire · 2026/10/5

Headlines are aggregated automatically and are not independently verified or edited by our team.

Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.

AnaptysBio discussion 0 comments

Add a comment